Developer docs
API playgroundTry for free, no card

Search company profiles

Haystack Oncology

Full company profile

uuid000077c

Namestring
Haystack Oncology
Legal namestring
Haystack Oncology Inc.
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
minimal residual disease testing, circulating tumor DNA detection, liquid biopsy diagnostics, cancer recurrence monitoring, tumor-informed MRD testing
Industry3 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1ctDNA MRD diagnostic testing
TypeOne Time License
Description

Haystack MRD is offered as a laboratory-developed test under CLIA regulations, sold to clinicians who order it for cancer patients. Revenue is generated per test performed. As a Quest Diagnostics subsidiary, the test is delivered through Quest's nationwide lab network, enabling broad access and scaling.

haystackmrd.com
2Technology licensing (Europe)
TypeLicensing Royalties
Description

Haystack Oncology licenses its MRD technology to international partners such as MVZ HPH in Germany, enabling localized testing delivery in Europe. This generates licensing revenue while expanding global patient access.

clpmag.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Haystack Oncology develops and commercializes Haystack MRD®, a tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology with a limit of detection of 0.0006%. The test is offered as a CLIA-regulated laboratory-developed test to oncologists for residual disease detection, neoadjuvant response assessment, treatment response monitoring, and recurrence surveillance across solid tumor cancers, and is also supplied to biopharma companies for clinical trial applications. The service is delivered exclusively through parent company Quest Diagnostics' nationwide laboratory network and internationally via technology licensing agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ctDNA testing using Haystack MRD identified clinical complete response at a median of 1.4 months compared to over 6 months for traditional imaging
+2 more records
Product overview1 text field

Haystack Oncology offers a single unified product: Haystack MRD®, a tumor-informed minimal residual disease (MRD) test that detects circulating tumor DNA (ctDNA) through liquid biopsy. The test uses proprietary dual-strand error-correction technology for exceptional sensitivity and specificity, enabling clinicians to detect residual or recurring disease in solid tumor cancer patients earlier than traditional imaging methods. The technology was developed by cancer genomics pioneers and further developed by parent company Quest Diagnostics. A European version called HPH MRD is available through a licensing agreement with MVZ HPH in Germany. The initial product was branded as Haystack Duo™ but has since been rebranded as Haystack MRD®.

Product and service2 records
1Haystack MRD®
CategoryCancer Diagnostics
Description

A tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology, with a limit of detection of 0.0006%. Sold to oncologists for neoadjuvant response assessment, residual disease detection, adjuvant therapy decision-making, treatment response monitoring, and recurrence surveillance in solid tumor cancer patients (breast, colorectal, ovarian, prostate, and others); also supplied to biopharma companies for clinical trial applications.

2HPH MRD
CategoryCancer Diagnostics
Description

A tumor-informed circulating tumor DNA blood test for detecting minimal residual disease in solid tumor cancer patients, launched in Europe through a licensing agreement with Haystack Oncology. Operated by MVZ HPH in Hamburg, Germany using Haystack's whole-genome sequencing technology and personalized panel design to enable localized European testing access.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMajorTypeStrategic or Co-development Partner
Description

City of Hope, one of the largest U.S. cancer research and treatment organizations, is implementing Haystack MRD in a multi-year clinical research program enrolling ~500 patients across 14 sites in major U.S. metropolitan areas. The program evaluates MRD detection, treatment response monitoring, and recurrence identification in breast, colorectal, ovarian, and prostate cancers.

Strategic tierRegionalTypeOEM/ Whitelabel/ Licensing Partner
Description

MVZ HPH in Hamburg, Germany licensed Haystack MRD technology to launch HPH MRD, a tumor-informed ctDNA blood test for detecting minimal residual disease in solid tumor cancer patients in Europe. The licensing agreement enables localized testing at HPH's Hamburg laboratories using Haystack's whole-genome sequencing technology, addressing a gap in European access to advanced MRD testing.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Memorial Sloan Kettering Cancer Center led the landmark clinical study validating Haystack MRD's clinical utility. The study, published in the New England Journal of Medicine in May 2025, demonstrated that ctDNA testing using Haystack MRD identified clinical complete response at a median of 1.4 months compared to over 6 months for traditional imaging, establishing the test's clinical evidence base.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Haystack Oncology

Cancer Diagnosticshaystackoncology.com

Haystack Oncology firmographics

Firmographics
Name
Haystack Oncology
Legal name
Haystack Oncology Inc.
Website
https://haystackoncology.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Haystack Oncology industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Minimal residual disease testing
  • Circulating tumor DNA detection
  • Liquid biopsy diagnostics
  • Cancer recurrence monitoring
  • Tumor-informed MRD testing

Where Haystack Oncology is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Haystack Oncology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. ctDNA MRD diagnostic testing: Haystack MRD is offered as a laboratory-developed test under CLIA regulations, sold to clinicians who order it for cancer patients. Revenue is generated per test performed. As a Quest Diagnostics subsidiary, the test is delivered through Quest's nationwide lab network, enabling broad access and scaling.
  2. Technology licensing (Europe): Haystack Oncology licenses its MRD technology to international partners such as MVZ HPH in Germany, enabling localized testing delivery in Europe. This generates licensing revenue while expanding global patient access.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Haystack Oncology product offering

Product offering

Core offering

Haystack Oncology develops and commercializes Haystack MRD®, a tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology with a limit of detection of 0.0006%. The test is offered as a CLIA-regulated laboratory-developed test to oncologists for residual disease detection, neoadjuvant response assessment, treatment response monitoring, and recurrence surveillance across solid tumor cancers, and is also supplied to biopharma companies for clinical trial applications. The service is delivered exclusively through parent company Quest Diagnostics' nationwide laboratory network and internationally via technology licensing agreements.

Product overview

Haystack Oncology offers a single unified product: Haystack MRD®, a tumor-informed minimal residual disease (MRD) test that detects circulating tumor DNA (ctDNA) through liquid biopsy. The test uses proprietary dual-strand error-correction technology for exceptional sensitivity and specificity, enabling clinicians to detect residual or recurring disease in solid tumor cancer patients earlier than traditional imaging methods. The technology was developed by cancer genomics pioneers and further developed by parent company Quest Diagnostics. A European version called HPH MRD is available through a licensing agreement with MVZ HPH in Germany. The initial product was branded as Haystack Duo™ but has since been rebranded as Haystack MRD®.

Differentiator

Problem solved

Functional benefit

Products and services

  • Haystack MRD® A tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology, with a limit of detection of 0.0006%. Sold to oncologists for neoadjuvant response assessment, residual disease detection, adjuvant therapy decision-making, treatment response monitoring, and recurrence surveillance in solid tumor cancer patients (breast, colorectal, ovarian, prostate, and others); also supplied to biopharma companies for clinical trial applications.
  • HPH MRD A tumor-informed circulating tumor DNA blood test for detecting minimal residual disease in solid tumor cancer patients, launched in Europe through a licensing agreement with Haystack Oncology. Operated by MVZ HPH in Hamburg, Germany using Haystack's whole-genome sequencing technology and personalized panel design to enable localized European testing access.

Quantifiable outcome

  • ctDNA testing using Haystack MRD identified clinical complete response at a median of 1.4 months compared to over 6 months for traditional imaging
  • +2 more outcomes

Companies that use Haystack Oncology

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Haystack Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Haystack Oncology partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered major and regional.

  • City of HopemajorStrategic or Co-development PartnerCity of Hope, one of the largest U.S. cancer research and treatment organizations, is implementing Haystack MRD in a multi-year clinical research program enrolling ~500 patients across 14 sites in major U.S. metropolitan areas. The program evaluates MRD detection, treatment response monitoring, and recurrence identification in breast, colorectal, ovarian, and prostate cancers.
  • MVZ HPH Institute for Pathology and HematopathologyregionalOEM/ Whitelabel/ Licensing PartnerMVZ HPH in Hamburg, Germany licensed Haystack MRD technology to launch HPH MRD, a tumor-informed ctDNA blood test for detecting minimal residual disease in solid tumor cancer patients in Europe. The licensing agreement enables localized testing at HPH's Hamburg laboratories using Haystack's whole-genome sequencing technology, addressing a gap in European access to advanced MRD testing.
  • Memorial Sloan Kettering Cancer CentermajorStrategic or Co-development PartnerMemorial Sloan Kettering Cancer Center led the landmark clinical study validating Haystack MRD's clinical utility. The study, published in the New England Journal of Medicine in May 2025, demonstrated that ctDNA testing using Haystack MRD identified clinical complete response at a median of 1.4 months compared to over 6 months for traditional imaging, establishing the test's clinical evidence base.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Haystack Oncology competitors and assessment

Company assessment

Market position

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Haystack Oncology social profiles

Digital presence

Haystack Oncology compliance and trust

Trust signal

Compliance2 records

Haystack Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Haystack Oncology leadership team

Management profile

Number of profiles

Profiles5 records

Haystack Oncology funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Haystack Oncology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Haystack Oncology

What does Haystack Oncology do?

Haystack Oncology develops and commercializes Haystack MRD®, a tumor-informed minimal residual disease (MRD) liquid biopsy test that detects circulating tumor DNA (ctDNA) in blood using proprietary dual-strand error-correction technology with a limit of detection of 0.0006%. The test is offered as a CLIA-regulated laboratory-developed test to oncologists for residual disease detection, neoadjuvant response assessment, treatment response monitoring, and recurrence surveillance across solid tumor cancers, and is also supplied to biopharma companies for clinical trial applications. The service is delivered exclusively through parent company Quest Diagnostics' nationwide laboratory network and internationally via technology licensing agreements.

Is Haystack Oncology a public or private company?

Haystack Oncology is a private company. It is classified as corporate owned and is currently operating.

When was Haystack Oncology founded?

Haystack Oncology was founded in 2021. It employs 51 to 100 people.

Where is Haystack Oncology based?

Haystack Oncology is headquartered in Baltimore, United States, in the North America region.

How does Haystack Oncology make money?

Two revenue lines are on record. ctDNA MRD diagnostic testing is the primary driver. The others are technology licensing (Europe).

Does Haystack Oncology have an API?

No public API is recorded for Haystack Oncology.

What industry is Haystack Oncology in?

Haystack Oncology's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Sub-Segments Transforming the Tumor Marker Testing Market LandscapeThe tumor marker testing market is projected to reach $27.23 billion by 2030, growing at a compound annual growth rate of 7.9%, driven by increased demand for early cancer detection, precision oncology adoption, and companion diagnostics. In June 2023, Quest Diagnostics acquired Haystack Oncology for $300 million to enhance its cancer diagnostics capabilities through minimal residual disease testing and liquid biopsy techniques. In April 2024, Swiss company RGCC International GmbH launched Onco-D-clare, a cancer detection test combining molecular biology with artificial neural networks to identify cancer before symptoms appear.CBS NewsBaltimore-based blood test makes treatment plans clearer for cancer patientsHaystackMRD, a blood test from Haystack Oncology, detects circulating tumor DNA to assess cancer recurrence. It was made clinically available in late 2024 and received FDA Breakthrough Device Designation in August. The test has been administered thousands of times, mostly in the U.S.openPR.comCompetitive Landscape: Leading Companies and New Entrants in the Biopsy Devices MarketThe Business Research Company released a market report projecting the global biopsy devices market will reach $4.95 billion by 2030, growing at a CAGR of 8.8%, driven by AI-assisted biopsy guidance systems, minimally invasive procedures, and precision oncology. In October 2025, Japan's Olympus Corporation launched the SecureFlex single-use fine-needle biopsy device featuring nitinol construction and a dual-beveled Raptor Tip for improved tissue sampling in EUS-FNB procedures. Additionally, Quest Diagnostics acquired Haystack Oncology in June 2023 to integrate circulating tumor DNA-based minimal residual disease testing into its diagnostic portfolio.openPR.comGlobal Trends Overview: The Rapid Evolution of the Genomic Cancer Panel and Profiling MarketThe genomic cancer panel and profiling market is projected to reach $15.45 billion by 2030, growing at a compound annual growth rate of 8.4%, driven by factors such as companion diagnostics expansion, liquid biopsy adoption, AI integration in genomic analyses, and affordable sequencing technologies. In June 2023, Quest Diagnostics acquired Haystack Oncology to strengthen its liquid biopsy and cancer detection capabilities, and in April 2025, Netherlands-based QIAGEN N.V. introduced QIAseq panels for next-generation sequencing capable of profiling over 700 genes.GlobeNewswireRapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel ExpansionThe global cell-free tumor DNA detection market is projected to grow from $2.58 billion in 2025 to $5.64 billion by 2030, representing a near doubling of market size over five years with compound annual growth rates of 16.9-17.2%. Key growth drivers include the rise of precision medicine, technological innovations in liquid biopsy analysis, integration with AI-based diagnostics, and increasing FDA approvals for personalized medicines which doubled from 12 to 26 between 2022 and 2023. Notable corporate activities include Twist Bioscience's February 2024 launch of a cfDNA Library Preparation Kit and Quest Diagnostics' April 2023 acquisition of Haystack Oncology to expand its liquid biopsy capabilities.YahooRapid Growth in Cell-Free Tumor DNA Detection Market: Forecast to Reach $5.64 Billion by 2030 as Advancements in Personalized Medicine Propel ExpansionThe cell-free tumor DNA detection market is projected to grow from $2.58 billion in 2025 to $5.64 billion by 2030, driven by increasing cancer prevalence, advances in molecular diagnostics, and rising demand for non-invasive testing technologies. Key industry developments include Quest Diagnostics' acquisition of Haystack Oncology in April 2023 and Twist Bioscience's launch of a cfDNA Library Preparation Kit in February 2024, alongside FDA-approved personalized medicines doubling from 12 to 26 between 2022 and 2023. Market leaders including Roche, Thermo Fisher Scientific, Labcorp, and Illumina continue advancing the sector, with North America currently leading while Asia-Pacific shows strong growth potential.openPR.comIn-Depth Examination of Segments, Industry Developments, and Key Players in the Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection MarketThe cell-free tumor DNA detection market is projected to grow to $5.64 billion by 2030, representing a compound annual growth rate of 16.9%, driven by precision medicine adoption, AI integration in diagnostics, and expanding healthcare infrastructure in emerging economies. Quest Diagnostics acquired Haystack Oncology in April 2023 to integrate liquid biopsy technology into its oncology offerings, while Twist Bioscience launched a cfDNA Library Preparation Kit in February 2024 to improve liquid biopsy test sensitivity and accuracy.